Gilead Beats Consensus; HIV Drugs Driving Growth Oct. 20, 2005 By Jennifer Boggs Riding the growth of its HIV franchise, Gilead Sciences Inc. reported solid earnings for the third quarter, beating consensus estimates by a penny. (Bioworld Today)Read More
